Wee Wei TEE

Cell Fate Plasticity and Chromatin Therapeutics
PhD – Developmental Biology, University of Cambridge, UK
Email: wwtee@imcb.a-star.edu.sg
Lab page: https://wwteelab.com/
SUMMARY
Wee Wei Tee is a Senior Principal Investigator and Deputy Division Director (Cancer Signalling and Therapy) at the Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR) and Assistant Professor at the Department of Physiology at National University of Singapore (NUS).
Wee Wei was mentored by Prof. Azim Surani at the University of Cambridge, UK and obtained his PhD with a Wellcome Trust PhD scholarship. A developmental biologist by training, Wee Wei then joined the laboratory of Prof. Danny Reinberg, a renowned chromatin biochemist and Howard Hughes Investigator at New York University School of Medicine, for his postdoctoral training.
The work in Wee Wei’s lab at IMCB focuses on disease epigenetics, cancer therapeutics, ageing, and regenerative medicine. His lab employs various genomic tools to interrogate genome-wide changes in chromatin states during development and disease, and utilises varied experimental tools such as bioinformatics, gene-editing, biochemistry as well as animal models and cell-based screens to uncover disease mechanisms. His lab is also actively involved in drug development efforts from target discovery to therapeutics development.
AWARDS & GRANTS
AWARDS
AWARDS
- 2024: NUS Yong Loo Lin School of Medicine Research Excellence Award
- 2022: European Molecular Biology Organization (EMBO) Global Investigator
- 2016: National Research Foundation (NRF) Fellowship
- 2015: National Institute of Health (NIH, US) Pathway to Independence Award (K99/R00)
Key Grants
- 2022: Singapore Therapeutics Development Review (STDR)
- 2021: National Medical Research Council (NMRC) Open Fund – Individual Research Grant (OF-IRG)
- 2020: National Medical Research Council (NMRC) Open Fund – Individual Research Grant (OF-IRG)
- 2020: Target Translation Consortium
- 2019: National Research Foundation, Singapore (NRF) Competitive Research Programme (CRP)
- 2016: National Research Foundation, Singapore (NRF) Fellowship
RESEARCH
- Disease epigenetics
- Cell fate plasticity
- Cancer therapeutics
- Ageing
- Regenerative medicine
Wee Wei’s lab aims to work towards formulating a comprehensive understanding of the epigenetic basis of human diseases, and we seek to achieve this by interfacing basic mechanistic studies with translational research.
PUBLICATIONS
- Transcriptional repression by a secondary DNA binding surface of DNA topoisomerase I safeguards against hypertranscription.
Lau MS, Hu Z, Zhao X, Tan YS, Liu J, Huang H, Yeo CJ, Leong HF, Grinchuk OV, Chan JK, Yan J, Tee WW.
Nat Commun. 2023 Oct 13;14(1):6464. doi: 10.1038/s41467-023-42078-9. PMID: 37833256; PMCID: PMC10576097. - Dependency of NELF-E-SLUG-KAT2B epigenetic axis in breast cancer carcinogenesis.
Zhang J, Hu Z, Chung HH, Tian Y, Lau KW, Ser Z, Lim YT, Sobota RM, Leong HF, Chen BJ, Yeo CJ, Tan SYX, Kang J, Tan DEK, Sou IF, McClurg UL, Lakshmanan M, Vaiyapuri TS, Raju A, Wong ESM, Tergaonkar V, Rajarethinam R, Pathak E, Tam WL, Tan EY, Tee WW.
Nat Commun. 2023 Apr 28;14(1):2439. doi:10.1038/s41467-023-38132-1. PMID: 37117180; PMCID: PMC10147683. - Maternal factor NELFA drives a 2C-like state in mouse embryonic stem cells.
Hu Z, Tan DEK, Chia G, Tan H, Leong HF, Chen BJ, Lau MS, Tan KYS, Bi X, Yang D, Ho YS, Wu B, Bao S, Wong ESM, Tee WW.
Nat Cell Biol. 2020 Feb;22(2):175-186. doi:10.1038/s41556-019-0453-8. Epub 2020 Jan 13. PMID: 31932739. - Chromatin features and the epigenetic regulation of pluripotency states in ESCs.
Tee WW, Reinberg D.
Development. 2014 Jun;141(12):2376-90. doi:10.1242/dev.096982. PMID: 24917497; PMCID: PMC4050692. - Erk1/2 activity promotes chromatin features and RNAPII phosphorylation at developmental promoters in mouse ESCs.
Tee WW, Shen SS, Oksuz O, Narendra V, Reinberg D.
Cell. 2014 Feb 13;156(4):678-90. doi: 10.1016/j.cell.2014.01.009. PMID: 24529373; PMCID: PMC4006806. - Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.
Tee WW, Pardo M, Theunissen TW, Yu L, Choudhary JS, Hajkova P, Surani MA.
Genes Dev. 2010 Dec 15;24(24):2772-7. doi:10.1101/gad.606110. PMID: 21159818; PMCID: PMC3003195.
PATENTS
- Markers of totipotency and methods of use (SG11201909866VB/ WO2018222139A1)
The present invention relates to methods of determining a potency state of an embryonic stem cell (ESC) in culture, comprising detecting the expression level of Negative Elongation Factor Complex Member A (Nelfa) in the embryonic stem cell, and correlating the expression level of Nelfa in said embryonic stem cell with that of a reference sample to determine the potency state of said embryonic stem cell. The present invention also provides methods of selecting totipotent-like embryonic stem cells (ESCs) from a population of embryonic stem cells in culture using an anti-Nelfa antigen binding protein. Methods of inducing totipotency in an embryonic stem cell in culture, methods of improving the reprogramming efficiency of a somatic cell into an induced pluripotent stem cell (iPSC) and methods of reprogramming a somatic cell into a totipotent stem cell by inducing Nelfa expression are also provided. Cells comprising an expression vector encoding Nelfa as well as kits to be used in the methods of the invention are also provided.
A*STAR celebrates International Women's Day

From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.
Get inspired by our #WomeninSTEM